Published in Genetics and Environmental Business Week, February 8th, 2007
In 2006, Celgene achieved exceptional results in its commercial, financial, clinical, regulatory and international performance, underscored by FDA approvals for Revlimd and Thalomid, and three product launches that delivered record results towards maximizing the commercial potential of Revlimid and Thalomid for the treatment of patients with certain blood cancers in the U.S.
The company's commercial performance was based on record total revenue and profits supported primarily by multiple product...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.